CLINICAL ROLE -
Video
Author(s):
Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.
Introducing Obecabtagene Autoleucel: A New Chapter in ALL Treatment
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
Thrombosis May Increase Risk of Cardiovascular Disease, Secondary Cancers in Myeloproliferative Neoplasms
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Momelotinib Shows Strong Efficacy in JAK-Exposed Myelofibrosis Patients
Zanubrutinib Plus Venetoclax and Obinutuzumab Yields Deep Remissions in Patients With Chronic Lymphocytic Leukemia